

PRESS RELEASE – FOR IMMEDIATE RELEASE

AP-HP : Georges Pompidou European Hospital and IntegraGen announce a cooperation agreement for access to a high-throughput sequencing platform

PARIS and EVRY, France (July 8, 2015) IntegraGen, a leading player in genome analysis, development and commercialization of molecular diagnostic tests, and the Georges Pompidou European Hospital (HEGP) recognized for its expertise in the fields of cancer, cardiovascular and renal pathologies of adult and emergency medicine, announced the signing of an agreement to develop the use of high-throughput sequencing techniques to improve the care of patients.

As part of this agreement, clinicians and biologists at HEGP will utilize sequencing capabilities in combination with bioinformatic analysis techniques developed jointly with IntegraGen to allow for the rapid interpretation of genomic data. This will enable the ability to refer patients, particular those with cancerous tumors, to targeted therapies.

Professor Pierre Laurent-Puig, an oncology biologist at HEGP emphasized: "With this agreement, oncologists and biologists at HEGP will now have access to a sequencing platform with the highest usable throughput for use in conjunction with clinical research projects. They will therefore benefit from the latest genome sequencing technologies and be able to develop specific tools for interpreting results which enable the personalized care of patients. This will result in a better ability to diagnose and treat each patient on an individual basis, depending on the genetic markers identified in their tumor. "

Anne Costa, Director of West Paris Hospital Group of the AP-HP, said: "This is a major advance in the treatment of cancer patients, and we are especially proud to now have the ability to offer patients followed at HEGP access to clinical research programs that foreshadows the future of medicine in the AP-HP."

Bernard Courtieu, CEO of IntegraGen stated, "The Georges Pompidou European Hospital and the Assistance Publique - Hôpitaux de Paris chose to partner with IntegraGen in order to access our expertise with clinical sequencing platforms and our bioinformatic analysis tools which permit high performance data interpretation. This is a major advance for the care of patients, and we are especially proud to put our expertise at the disposal of prominent hospital centers like HEGP. This agreement confirms our team's excellence relative to sequencing and genomic analysis and will contribute to the continued growth of our genomic services activities."

ABOUT INTEGRAGEN

IntegraGen is a company that specializes in deciphering the human genome and produces relevant and easily interpretable data for academic and private laboratories. IntegraGen's oncology efforts provide researchers and clinicians with sophisticated tools for analysis and therapeutic individualization of treatment approaches allowing them to tailor therapy to the genetic profiles of patients. For autism, IntegraGen has developed the ARISk® Test, the first test marketed in the United States to assess the risk of autism spectrum disorder in children.

As of December 31, 2014, IntegraGen had 34 employees and generated revenue of €6 million during 2014. Based in the Evry Genopole, IntegraGen also has an office in the U.S. located in Cambridge, Massachusetts.

IntegraGen is listed on Alternext of Euronext Paris (ISIN: FR0010908723 - Ticker: ALINT - Eligible for PEA-SME)

For more information about IntegraGen visit www.integragen.com.



AP-HP

The AP-HP (Assistance Publique - Hôpitaux de Paris) is the Paris area's University Medical Center (UMC) and the leading UMC in Europe. Its 39 hospitals treat over 7 million patients each year either in consultation, for emergency care, for scheduled hospitalizations, or for home hospitalization. The AP-HP provides a public health service for all, 24h a day as a necessity for patients and with pride. The AP-HP is the largest employer in the Paris region with 95 000 people including doctors, researchers, paramedicals, administrative staff and workers.

For more information about the AP-HP visit www.aphp.fr

CONTACTS

INTEGRAGEN

Bernard COURTIEU
President and CEO

Laurence RIOT LAMOTTE
Chief Financial Officer
contact@integragen.com
Tel.: +33 (0)1 60 91 09 00

NEWCAP

Investor and Media Relations

Emmanuel HUYNH
Louis-Victor DELOUVRIER
Nicolas MERIGEAU

integragen@newcap.fr
Tel. : +33 (0)1 44 71 94 94

SERVICE DE PRESSE DE L'AP-HP

Anne-Cécile Bard, Clémence Rémy
service.presse@sap.aphp.fr
Tel. : +33 (0)1 40 27 37 22

COMMUNICATION HEGP

Valérie Munos
Tel. : +33 (0)1 59 09 21 06